Skip to main content
Premium Trial:

Request an Annual Quote

Phenomenome, Polymedco Ink Pact to Commercialize Mass Spec-based Colorectal Cancer Test

NEW YORK (GenomeWeb News) – Phenomenome Discoveries has granted Polymedco Cancer Diagnostic Products a license to commercialize Phenomenome's mass spectrometry-based blood test for colorectal cancer in the US.

The test uses triple quadrupole mass spec technology to detect a deficiency in novel anti-cancer and anti-inflammatory metabolites in a blood sample, which Phenomenome said it has discovered occurs in nine out of 10 patients with colorectal cancer.

Dayan Goodenowe, president and CEO of Phenomenome, said in a statement that the two firms submitted an application with the US Food and Drug Administration last month for premarket review, "and we look forward to receiving approval and moving ahead with our shared commercialization strategy."

Financial and other terms of the deal were not disclosed.

Based in Saskatoon, Saskatchewan, Phenomenome discovers and develops biomarkers for cancer and neurodegenerative disorders. Polymedco is headquartered in Cortlandt Manor, NY, and manufactures, markets, and distributes clinical diagnostic kits and devices in the area of oncology.